New drug duo aims to outsmart melanoma that resists standard treatment
NCT ID NCT05130177
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, in 8 adults with melanoma that stopped responding to PD-1 inhibitors. The goal is to see if the combination can shrink tumors or stop them from growing. The study is active but no longer recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zimberelimab and Domvanalimab (two immunotherapy drugs that help the immune system attack cancer)
What this could lead to
If successful, this combination could offer a new treatment option for people with melanoma that no longer responds to standard immunotherapy.
What could go wrong
This is a very small early-phase trial with only 8 participants, so results may not apply to everyone. The drugs can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States